Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05462496 · ClinicalTrials.gov registry record · Phase 2

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

A Phase 2 study of Pancreatic Cancer, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
Phase 2
Development phase
25
Enrollment target
1
Study location

NCT05462496 is a Phase 2 study of Pancreatic Cancer that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 25 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05462496, a Phase 2 study of Pancreatic Cancer, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
Phase 2
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG Pembrolizumab
  • PROCEDURE Biopsy
  • DRUG Metronidazole
  • DRUG FOLFIRINOX
  • DRUG Ciprofloxacin

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2023-03-16
Est. Completion 2028-04
Phase Phase 2

Sponsor

Icahn School of Medicine at Mount Sinai

708 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05462496

The ClinicalTrials.gov registry entry for NCT05462496 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT05462496 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05462496 about?

NCT05462496 is a clinical study titled "Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer". A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.

What is the current status of trial NCT05462496?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2023-03-16. Estimated completion is 2028-04.

What conditions does trial NCT05462496 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT05462496?

The interventions under investigation include: Pembrolizumab (DRUG), Biopsy (PROCEDURE), Metronidazole (DRUG), FOLFIRINOX (DRUG), Ciprofloxacin (DRUG).

Who is sponsoring clinical trial NCT05462496?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05462496 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.